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resumo 
 
 
A hipertensão arterial pulmonar (HAP) é uma doença rara e letal, caracterizada 
pela remodelação da vasculatura pulmonar, devido a uma proliferação celular 
excessiva e diminuição da apoptose. Estas alterações levam ao aumento da 
resistência e pressão arterial pulmonares, culminando em insuficiência 
cardíaca direita. O tratamento atual é limitado, não oferecendo uma cura e, 
portanto, é necessária mais investigação para encontrar novos alvos 
terapêuticos. Neste contexto, a via da survivina, uma molécula que inibe a 
apoptose e promove a proliferação e cujos níveis estão aumentados na HAP, 
parece promissora. O objetivo deste trabalho foi avaliar o efeito do 
terameprocol, um antagonista da survivina, na proliferação e apoptose de 
células musculares lisas na HAP. Foi utilizado o modelo experimental de HAP 
induzida por monocrotalina (MCT). Ratos Wistar foram injetados com MCT (60 
mg/kg, sc) para a indução da doença e, após 21 dias foram sacrificados, o 
coração e os pulmões foram removidos e a artéria pulmonar do lobo superior 
esquerdo foi dissecada. A adventícia e íntima foram removidas da artéria e as 
células musculares lisas da média foram isoladas através de um método 
enzimático. Foi realizada uma cultura primária de células musculares lisas que 
foram tratadas com diferentes concentrações de terameprocol. Em seguida, 
foram realizados ensaios para avaliar a apoptose (TUNEL) e proliferação 
(BrdU e exclusão por trypan blue) das células musculares lisas. Os resultados 
mostraram que o terameprocol inibe a proliferação e induz a apoptose das 
células musculares lisas da artéria pulmonar de ratos com HAP induzida pela 
MCT, sugerindo que a via da survivina pode constituir um novo alvo 
terapêutico a ser investigado na HAP. 
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abstract 
 
Pulmonary arterial hypertension (PAH) is a rare and lethal disease, 
characterized by remodeling of the pulmonary vasculature due to excessive 
cellular proliferation and decreased apoptosis. These alterations lead to 
increased pulmonary arterial resistance and pressure, culminating in right heart 
failure. The current treatment is limited, not affording a cure and thus, more 
research is needed to find new therapeutic targets. In this context, targeting 
survivin, a molecule that inhibits apoptosis and promotes proliferation and 
reported to be increased in PAH, seems promising. The aim of this work was to 
evaluate the effect of terameprocol, an antagonist of survivin, in the 
proliferation and apoptosis of smooth muscle cells in PAH. We used the 
experimental model of PAH induced by monocrotaline (MCT). Wistar rats were 
injected with MCT (60 mg/kg, sc) to induce the disease and after 21 days, they 
were euthanized, their heart and lungs were removed and the pulmonary artery 
from the left upper lobe was dissected. The adventitia and intima were removed 
from the artery and the smooth muscle cells from the media were isolated 
through an enzymatic method. The resultant primary cultures of smooth muscle 
cells were treated with different concentrations of terameprocol. Then, assays 
were performed to evaluate smooth muscle cell apoptosis (TUNEL assay) and 
proliferation (BrdU and trypan blue exclusion assays). The results showed that 
terameprocol inhibits proliferation and promotes apoptosis of pulmonary artery 
smooth muscle cells from rats with MCT-induced PAH, suggesting that survivin 
pathway can be seen as a new therapeutic target to be explored in PAH. 
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1. Introduction 
Pulmonary arterial hypertension (PAH) is a disease that although rare, is fatal if 
untreated. It is characterized by vasoconstriction, thrombosis in situ, inflammation and a 
vascular remodeling that result from the excessive proliferation of endothelial cells, 
smooth muscle cells and fibroblasts of the pulmonary artery wall, and decreased cellular 
apoptosis [1, 2]. These alterations progressively lead to the pulmonary artery lumen 
obstruction, increasing pulmonary vascular resistance and imposing pressure overload 
to the right ventricle (RV). Despite the initial RV adaptation, heart failure and 
premature death will eventually occur [1, 3]. Several molecular pathways have been 
reported to be involved in these structural alterations of the pulmonary artery wall but 
only a few were found to be therapeutically relevant. For instance, treatments with 
prostacyclin analogs, endothelin-1 receptor blockers, or phosphodiesterase type 5 
inhibitors were all shown to be of benefit [1]. Nevertheless, the great majority of 
patients remain symptomatic and mortality rates still elevated [3]. In order to develop 
effective therapeutic targets, more research is needed on the cellular and molecular 
mechanisms responsible for the pathobiology of this disease.  
Survivin is an anti-apoptotic and proliferative molecule, reported to be increased in 
PAH. It was shown that inhibition of survivin function by inhaled adenoviral gene 
therapy with a survivin mutant (Thr34Ala) reduced the vascular remodeling observed in 
PAH induced by monocrotaline in an animal model [4]. Other strategies, such as 
terameprocol, were reported to inhibit the growth of tumors by targeting Sp1 regulated 
proteins, including cdc2 and survivin [5, 6]. As cancer, PAH is also a disease 
characterized by excessive proliferation and impaired apoptosis; however, the role of 
terameprocol in PAH is still unknown. Thus, the present work focus in the study of the 
effect of terameprocol in the proliferation and apoptosis of smooth muscle cells in an 
animal model of PAH induced by monocrotaline administration, through the use of 
primary smooth muscle cells cultures. 
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2. Pulmonary arterial hypertension 
2.1. Definition, classification and epidemiology  
 Pulmonary arterial hypertension (PAH) was initially described by the German 
physician and pathologist Ernst von Romberg in 1891 and only in 1973 the World 
Health Organization (WHO) standardized clinical and pathological nomenclature of 
PAH. Successively WHO has continued with regular conventions on this issue (Evian 
1998, Venice 2003 and Dana Point 2008) [7]. The disease is now defined as a mean 
pulmonary artery pressure greater than or equal to 25 mmHg at rest with a mean 
pulmonary-capillary wedge pressure less than or equal to 15 mmHg [8]. After the 2008 
4
th
 World Symposium on Pulmonary Hypertension classification, pulmonary 
hypertension (PH) was subdivided into six groups (Table 1) [9, 10]. 
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Table 1 – Clinic classification of pulmonary hypertension according to the 4th World Symposium on 
Pulmonary Hypertension held in Dana Point in 2008. 
Group 1. Pulmonary arterial hypertension (PAH) 
1.1. Idiopathic PAH (IPAH) 
1.2. Heritable 
1.2.1. BMPRII gene 
1.2.2. ALK1,endoglin genes (with or without hereditary hemorrhagic telangiectasia) 
1.2.3. Unknown 
1.3. Drugs and toxins induced 
1.4. Associated with: 
1.4.1. Connective tissue diseases 
1.4.2. HIV infection 
1.4.3. Portal hypertension 
1.4.4. Congenital heart diseases 
1.4.5. Schistosomiasis 
1.4.6. Chronic haemolitic anaemia 
1.5. Persistent pulmonary hypertension of the newborn 
Group 1’. Pulmonay veno-occlusive disease (PVOD) and/or pulmonary capillary haemangiomatosis 
(PCH) 
Group 2. Pulmonary hypertension due to left heart disease 
2.1. Systolic dysfunction 
2.2. Diastolic dysfunction 
2.3. Valvular disease 
Group 3. Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Sleep-disordered breathing 
3.4. Chronic exposure to high altitude 
3.5. Broncho pulmonary dysplasia  
3.6. Developmental abnormalities 
Group 4. Chronic thromboembolic pulmonary hypertension (CTPH) 
Group 5. Pulmonary hypertension with unclear and/or multifactorial mechanisms 
5.1. Haematologic disorders: myeloproliferative disorders, splenectomy 
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3. Metabolic disorders: Glycogen storage disease, Gaucher disease, thyroid disorders 
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis 
Legend: ALK1 = activin receptor-like kinase 1; BMPRII = bone morphogenetic protein receptor, type II; 
HIV = human immunodeficiency virus 
 
PAH is a rare disease with an incidence of approximately 2.4 cases per million 
diagnosed per year and a prevalence of approximately 15 cases per million diagnosed 
per year, according to a French population study [11]. Two-thirds of affected persons 
are women and the majority of patients are diagnosed with 41-50 years of age [12]. In 
systemic sclerosis (a connective tissue disease), the prevalence of PAH has been 
estimated to be 7.8-23%. In addition, PAH can be diagnosed in 0.5% of patients with 
HIV infection and in 2-5% of patients suffering from portal hypertension. It is also 
estimated that 10% of patients with hemoglobinopathies (such as sickle cell disease and 
thalassaemia) develop moderate to severe pulmonary hypertension [7, 10]. 
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2.2. Genetic association  
 A rare group of patients with hereditary hemorrhagic telangiectasia and 
idiopathic PAH present specific mutations in genes encoding activin receptor-like 
kinase type 1 (ALK1), a member of the transforming growth factor-β (TGF-β) 
superfamily, or endoglin, an endothelial cell-specific TGF-β superfamily coreceptor 
[13-15]. However, a more prevalent cohort of patients carries mutations in another 
member of the TGF-β superfamily, the bone morphogenetic protein receptor type II 
(BMPRII), that is encoded by BMPRII gene, located on the chromosome 2q33 [16].  
In general, upon a ligand belonging to the TGF-β superfamily binds to a 
complex of type II and type I serine/threonine kinase transmembrane receptors, the 
receptor II phosphorylates the bound type I receptor, which, in turn, phosphorylates one 
of the Smad family proteins that translocate for the nucleus allowing their binding to 
DNA, and the regulation of the transcription of specific target genes (Figure 1) [17, 18]. 
 
 
 
Figure 1 – Signal transduction by TGF-β family members. In most cells TGF-β interacts with TβRII 
(type II receptor) and ALK5 (type I receptor), but in endothelial cells it can also signal via ALK1 (type I 
receptor). BMPs signal via BMPRII, ActRIIA and ActRIIB (type II receptors), and type I receptors 
ALK1/2/3 and 6. ALK5 induces phosphorylation of Smad2 and Smad3, and ALK1/2/3 and 6 mediate 
phosphorylation of Smad1 and 5. Activated Smads form complexes with Smad4, which accumulate in the 
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nucleus, where they interact with transcription factors (TF) to regulate the expression of specific target 
genes (adapted from [18]). 
 
Over 140 mutations in BMPRII have been reported in patients with heritable 
PAH [19]. The BMPRII protein comprises ligand-binding, kinase and cytoplasmic 
domains. Mutations have been identified in all of these regions, including partial gene 
deletions, missense, nonsense and frameshift mutations. The majority of mutations in 
BMPRII (approximately 70%) are nonsense or frameshift mutations, which are likely to 
result in the transcript being degraded [17]. Rudarakanchana et al. [20] showed that 
substitution of cysteine residues in the ligand binding or/and kinase domain of BMPRII 
prevented their trafficking to the cell surface, with retention in the endoplasmic 
reticulum. They also verified that in BMPRII mutants containing non-cysteine missense 
mutations in the kinase domain, the BMPRII attained the cell surface, but failed to 
activate a BMP/Smad response. In addition, missense mutations in the cytoplasmic 
region of BMPRII, not affect the location of BMPRII in the cell surface and BMPRII 
retained their ability to activate a BMP/Smad response.  
In the adult, BMPRII is expressed predominantly in the pulmonary endothelial 
cells (ECs), medial smooth muscle cells (SMCs), and macrophages [21]. The mutations 
in BMPRII that lead to PAH exert their action predominantly by alterations in 
endothelium and/or smooth muscle [22]. Under normal conditions, BMP ligands bind 
BMPRII to suppress the growth of vascular SMCs [23, 24]. In addition, binding of 
BMP2 and BMP7 to BMPRII in pulmonary endothelium leads to protection from 
apoptosis [25]. It has been reported that inhibition of BMPRII using specific siRNA in 
human pulmonary artery ECs (PAECs) induced ECs apoptosis through activation of 
caspase-3 [25].  
2.3. Physiological changes 
The vascular wall is organized into three layers: an inner layer composed of 
endothelial cells (intima), a middle layer of smooth muscle cells (media), and an outer 
layer, mostly composed by fibroblasts (adventitia). In PAH it is verified structural 
changes in all these layers [26, 27], which include intimal hyperplasia, medial 
hypertrophy and hyperplasia, adventitia proliferation, formation of a layer of 
myofibroblasts and extracellular matrix between the endothelium and the internal elastic 
lamina (termed neointima) and the occurrence of plexiform lesions, which result from 
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the focal proliferation of endothelial cells and are lined by myofibroblasts, smooth 
muscle cells and connective tissue (Figure 2) [1, 27, 28]. With time, this vascular 
remodeling reduces the lumen diameter of pulmonary arteries leading to a rise in 
pulmonary vascular resistance and hence to an elevated pulmonary artery pressure 
(PAP). In addition, muscularisation of normally non-muscular arteries occurs [29]. 
Thrombosis in situ (Figure 2) and infiltration of inflammatory cells are also observed 
during PAH development [1]. 
 
 
Figure 2 – Structural changes in the pulmonary arterial wall, in pulmonary arterial hypertension (adapted 
from [30]). 
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Right ventricular hypertrophy can also be verified during PAH. It develops when 
the right ventricle works against increased resistance in the pulmonary circulation. 
Cardiac hypertrophy develops in PAH, at first as a compensatory mechanism [27]. The 
right ventricle accumulates muscle mass (via elevated protein synthesis and an increase 
in myocyte size), and the right ventricle wall thickens [3]. In addition, it also assumes a 
more-rounded shape, compressing the left ventricle [31]. Cardiac output is initially 
maintained, but with persistent elevated resistance, progressive contractile dysfunction 
occurs and can lead to right heart failure [3].  
 
2.4. Molecular mechanisms  
 In PAH it is verified an imbalance in the production of several mediators with 
important functions in controlling the vasoconstriction, cellular proliferation, apoptosis 
and platelet aggregation. Table 2 lists the changes reported in some of these mediators 
in PAH. Some of them will be focused in more detail in the section “Cellular changes”.  
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Table 2 – Cellular mediators and their changes in pulmonary arterial hypertension. 
 Physiological effects Levels in PAH  
Mediator Vascular 
constriction 
Cell 
proliferation 
Platelet 
aggregation 
Apoptosis Serum Lung Reference 
Prostacyclin 
(PGI2) 
- - -    [26, 32] 
Thromboxane 
A2 (TXA2) 
+ + +    [33] 
Serotonin (5-
HT) 
+ + +    [34-37] 
Nitric oxide 
(NO) 
- - - +   [38, 39] 
Endothelin-1 
(ET-1) 
+ +     [26, 29, 
40] 
Vasoactive 
intestinal 
peptide 
- - - -   [26, 33, 
41] 
Adrenomedullin - -     [33, 42] 
Angiotensin-II  +     [43] 
Urotensin-II + +     [44] 
Atrial 
natriuretic 
peptide; Brain 
natriuretic 
peptide 
      [45] 
Angiopoietin-1    -   [46, 47] 
Vascular 
endothelial 
growth factor 
 +  -   [48] 
Platelet derived 
growth factor 
+ + - -   [38, 49, 
50] 
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2.5. Cellular changes 
In PAH progression it is verified structural alterations in the three layers of the 
vascular wall. In addition, functional alterations in the cell types that make part of these 
layers and also other cell types are verified during PAH development. Understanding 
the interplay between these cells is important to follow the development of the disease. 
Some changes that occur in endothelial cells, smooth muscle cells, fibroblasts, 
inflammatory cells and platelets in PAH are listed below. 
2.5.1. Endothelial cells 
  Endothelial cells are known to be major regulators of vascular function 
[51]. They are equipped with mechanisms to sense differences in the oxygen (O2) 
supply, which include O2-sensitive NADPH oxidases, endothelial nitric oxide 
synthases, and heme oxygenases [52]. In addition, the hypoxia-inducible transcription 
factor (HIF) family is also involved in adaptations to changes in O2 tension [53]. 
Although the mechanisms that mediate the damage to the endothelium are largely 
unknown, it seems that insults such as from chronic hypoxia, inflammation, viral 
infection, mechanical stretch or shear stress resulting from the blood flow, activates the 
endothelium [54] and results in accelerated endothelial cell apoptosis. The death of ECs 
leads to the appearance of apoptotic-resistant and hyper-proliferative ECs, which can 
lead to vascular remodeling and luminal obstruction [55, 56].  
In PAH endothelial dysfunction can be reflected by a reduction in the 
production of vasodilators like NO and PGI2, and increased production of 
vasoconstrictors like ET-1 and TXA2 [51].  
Nitric oxide is produced by a family of enzymes called nitric oxide 
synthases (NOS). There are three isoforms of NOS: endothelial (eNOS), inducible 
(iNOS) and neuronal (nNOS). In blood vessels, NO is produced and released by the 
endothelium. It was shown that eNOS is the primary mediator of the effects of NO in 
the pulmonary circulation [38]. The eNOS converts the amino acid L-arginine into two 
products; NO and L-citrulline. Upon its release by endothelium, NO diffuses into 
vascular SMCs where it stimulates soluble guanylate cyclase (sGC) to produce the 
second messenger cyclic guanosine monophosphate (cGMP) from guanosine 
triphosphate (GTP), leading to dilatation of blood vessels via dephosphorylation of 
myosin light chain. NO is a vasodilator with the ability to inhibit proliferation and 
platelet aggregation and promote apoptosis of vascular SMCs [38, 39]. 
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Phosphodiesterases (PDE) are enzymes that regulate intracellular signals by degrading 
second messengers such as cGMP and cyclic adenosine monophosphate (cAMP). PDE 
type 5 is expressed predominantly in the lungs and pulmonary vasculature [38]. The NO 
pathway is impaired in several ways in PAH. NOS expression is depressed [57]. 
Moreover, PDE type 5 is increased in pulmonary artery SMCs (PASMCs), which leads 
to inactivation of cGMP [58]. The production of endogenous NOS inhibitors, 
asymmetrical and symmetrical dimethylarginines (ADMA and SDMA, respectively), is 
enhanced in PH [59]. Finally, sGC expression is upregulated in human PAH, as a 
compensatory mechanism [60].  
Prostacyclin is a product of arachidonate metabolism [61, 62]. Following 
its synthesis and release, PGI2 exerts its effects in a paracrine manner, is not stored, and 
is rapidly converted to an inactive metabolite, 6-ketoprostaglandin F1α [61]. In blood 
vessels, it is produced by endothelial cells and released to act upon neighboring vascular 
SMCs as well as circulating platelets, through plasma membrane prostacyclin receptors, 
which are G protein coupled receptors [61, 62]. PGI2 binds to its receptor and leads to 
the activation of adenylyl cyclase, accumulation of the second messenger cAMP, and 
activation of its main intracellular effector, the cAMP-dependent protein kinase, PKA 
[62]. PGI2 is a vasodilator that inhibits the proliferation of vascular SMCs and decrease 
platelet aggregation [26]. It was shown that PGI2 synthesis is decreased in endothelial 
cells from PAH patients. Analysis of urinary metabolites of PGI2 showed a decrease in 
the amount of excreted 6-ketoprostaglandin F1α in patients with idiopathic PAH [32]. 
Moreover, pulmonary ECs of PAH patients are characterized by reduced expression of 
prostacyclin synthase [63]. Prostacyclin receptor expression is also reduced in 
pulmonary artery smooth muscle in severe PH [64].  
Endothelin-1 is mainly produced by endothelial cells and acts via two 
receptors: ETA and ETB. Both receptors are found in PASMCs and mediate 
vasoconstriction and proliferation, whereas only the ETB receptor is present in 
endothelial cells and mediates NO and PGI2 release, leading to vasodilatation. Signaling 
pathways involve a rapid increase in intracellular calcium [26, 29]. Lung and circulating 
ET-1 levels are increased in PAH patients [40]. 
Like prostacyclin, thromboxane results from arachidonate metabolism 
[62, 65]. TXA2 is synthesized by platelets and endothelial cells and binds to its 
receptors, which are G protein coupled receptors, widely distributed among different 
cell types, such as platelets, endothelial cells, smooth muscle cells, cardiac myocytes 
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and epithelial cells [65, 66]. Thromboxane receptors activation is involved in a variety 
of processes, including thrombosis, modulation of the immune response, inflammatory 
lung disease, and hypertension. A multitude of signaling cascades are activated by 
TXA2, and involve downstream effectors such as inositol triphosphate/diacylglycerol, 
cAMP, Ras, Rho, phosphoinositide-3 kinase, PKC and PKA. These different signaling 
pathways vary in a cell- and organ-specific manner [66]. TXA2 is a vasoconstrictor that 
stimulates platelet aggregation and has mitogenic effects in SMCs [33]. It was verified 
an increase in the urinary excretion of 11-dehydro-thromboxane B2 (a stable metabolite 
of thromboxane A2) [32] and in total body synthesis of TXA2 in patients with idiopathic 
PAH [67].  
 Importantly, an increase in ECs permeability seems to contribute to the 
pathogenesis of PAH [51]. The GTPases RhoA and Rac1 play opposing roles in the 
regulation of ECs barrier function. Stimuli such as thrombin activate RhoA/ROCK, 
which increases permeability. Mediators such as PGI2 stimulate Rac1/p21-activated 
kinase, which promotes barrier integrity [51, 68]. It was shown that PAECs cultured 
from chronically hypoxic piglets demonstrate low Rac1 and high RhoA activities, 
which correlate with increased permeability [69]. Thus, increasing the permeability of 
ECs, mediators produced by these cells can be released and act on neighboring 
structures, including the smooth muscle cells in media layer. It has been shown that an 
altered production of the endothelial vasoactive mediators NO, PGI2, ET-1, and TXA2 
can affect the growth of the SMCs, leading to the development of pulmonary vascular 
hypertrophy and structural remodeling [70]. In addition, ECs can be involved in the 
thrombosis process that contributes to PAH. They can regulate the thrombotic-
antithrombotic balance and participate in the coagulation process by activating factor X, 
facilitating the formation of the thrombin-activating prothrombinase complex and 
activating the extrinsic pathway of coagulation via release of tissue factor [71]. On the 
other hand, ECs can also inhibit thrombosis and promote fibrinolysis. They produce and 
release NO and PGI2, two important inhibitors of platelet aggregation, preventing 
thrombosis. Endothelial cells participate in the fibrinolytic process through the synthesis 
and release of the profibrinolytic tissue plasminogen activator (t-PA) that activates 
plasminogen in the fibrinolytic cascade. In addition, endothelial cells also produce the 
antifibrinolytic/prothrombotic plasminogen activator inhibitor (PAI)-1 [71]. 
 PAH-related alterations in ECs also involve adaptations in mitochondrial 
metabolism. It was verified a shift in glucose metabolism from oxidative 
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phosphorylation to glycolysis, leading to the production of less energy [27]. Xu and 
colleagues verified, through positron tomography scan, a significantly higher uptake of 
glucose in PAECs from patients with idiopathic PAH compared with ECs from control 
individuals, confirming the increased glycolytic rate. In addition, they demonstrated that 
oxygen consumption, the number of mitochondria per cell and the mitochondrial DNA 
content of idiopathic PAH endothelial cells was lowered in comparison with ECs from 
control individuals [72]. The enzyme pyruvate dehydrogenase kinase (PDK) seems to 
be activated in PAH and is responsible for the phosphorylation and inhibition of 
pyruvate dehydrogenase (PDH), which is responsible for the oxidation of pyruvate, 
yielding acetyl-coenzyme A. PDK activation thus impairs the Krebs cycle and creates a 
glycolytic shift in glucose metabolism [1]. Dichloroacetate, which inactivates PDK, had 
been shown to regress experimental PAH, both in hypoxic and monocrotaline models 
[73, 74]. 
 Alterations in the intracellular trafficking, which is mediated by a group 
of proteins, including membrane tethers, SNAREs (SNAP receptors) and SNAPs 
(soluble NSF association proteins), and the ATPase N-ethylmaleimide-sensitive factor 
(NSF) were also reported in PAH [75, 76]. It was verified that monocrotaline pyrrole 
(the bioactive form of monocrotaline)-treated PAECs in culture showed enlarged 
endoplasmic reticulum and Golgi stacks by electron microscopy within 48-96 h after the 
treatment [77]. In addition, it was shown the loss of the cell surface raft/caveolar protein 
caveolin-1 (cav-1) in PAECs in rat lungs within 48 h after the treatment with 
monocrotaline [78]. It has been showed that monocrotaline and hypoxia disrupt the 
molecular machinery of vesicular trafficking at the level of Golgi tethers, SNARES, and 
SNAPS (“Golgi blockade”) [79]. Consequences of this disruption include the trapping 
of cav-1 in the Golgi of PAECs, the loss of eNOS from plasma membrane caveolae and 
its sequestration in intracytoplasmic compartments, and loss of NO production [80]. 
Murata and colleagues [81] showed that eNOS was co-trapped in the Golgi with cav-1 
in endothelial cells exposed to hypoxia. 
 
2.5.2. Smooth muscle cells 
 Smooth muscle cells are stretch sensors, once cyclic stretch regulates the 
functions of vascular SMCs activating intracellular signaling networks, which regulate 
gene expression and thus cellular functions [82]. 
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 It was observed SMCs with different phenotypes. These phenotypes are 
characterized by changes in morphology, proliferation and migration rates, and in the 
expression of different marker proteins. The resulting phenotype diversity of SMCs, 
ranging from the contractile to the synthetic, appears to be related to genetic and 
environmental factors, such as extracellular matrix components and physical factors 
(stretch and shear stress) [83]. The different phenotypes observed between SMCs are 
seen in SMCs of different vessels as well as amongst SMCs within the same vessel [83]. 
Contractile SMCs are elongated, spindle-shaped cells, whereas synthetic SMCs are less 
elongated and present cobblestone morphology, also called epithelioid or rhomboid. 
Synthetic SMCs contain a high number of organelles involved in protein synthesis, 
whereas there are largely replaced by contractile filaments in contractile SMCs. In 
addition, synthetic SMCs exhibit higher growth rates and higher migratory activity than 
contractile SMCs [83].  
There are some difficulties in identify SMCs phenotypes, because the 
markers used are also expressed in a variety of other cell types either under normal or 
pathologic conditions [84]. Currently, the two marker proteins that provide the best 
definition of a mature contractile SMC phenotype are smooth muscle-myosin heavy 
chain (SM-MHC) and smoothelin. SM-MHC expression has never been detected in 
non-SMCs in vivo. Smoothelin complements SM-MHC as a contractile SMC marker in 
that it appears to be more sensitive [83, 84]. Other markers expressed in a contractile 
SMC include α-smooth muscle actin (α-SMA), desmin, smooth muscle-calponin and h-
caldesmon [83, 85]. In vascular repair during injury and/or vascular adaptation, it is 
verified that vascular SMCs “switch” to a non-contractile, proliferative and migratory 
phenotype. This phenotypic switch is under tight control and is often reversible, but 
under certain circumstances can contribute to vascular disease states, like hypertension 
[86]. 
Ions, including K
+
, Ca
2+
, Na
+
 and Cl
-
 and their channels have been 
reported to have an important role in both apoptosis and cell proliferation of SMCs. An 
imbalance that favors proliferation instead apoptosis, leading to an increase in cell 
population is reported in several diseases, including PAH. Regarding the K
+
 channels, 
the four main functional classes are: (i) voltage-gated (KV) K
+
 channels; (ii) Ca
2+
-
activated (KCa) K
+
 channels; (iii) inwardly rectifying (KIR) K
+
 channels, of which ATP-
sensitive (KATP) K
+
 channels are a member and (iv) two-pore domain (K2P) K
+
 channels 
[87]. When K
+
 channels are blocked (or K
+
 channels gene expression is downregulated), 
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the membrane depolarizes and opens voltage-dependent Ca
2+
 channels (VDCC), 
promoting a Ca
2+
 influx, increasing cytosolic calcium concentration ([Ca
2+
]cyt) and 
causing PASMCs contraction. Conversely, when K
+
 channels are activated (or K
+
 
channels gene expression is upregulated), the membrane hyperpolarizes and closes 
VDCC, inhibiting Ca
2+
 influx, decreasing [Ca
2+
]cyt and causing vasodilatation [87]. 
Intracellular Ca
2+
 is also an important second messenger for cell migration and 
proliferation. Ca
2+
 influx through VDCC activates transcription factors, such as CREB, 
NF-AT and NF-kB that are involved in cell proliferation, protein synthesis and 
inflammation and Ca
2+
 is also required for cell-cycle progression. In apoptosis, K
+
 
channels mediate the K
+
 efflux that is necessary for apoptotic volume decrease (AVD). 
K
+
 efflux also leads to the decrease of [K
+
]cyt, releasing  the  inhibition of caspases [87]. 
It was reported a defect in the gene expression and attenuated function of KV
 
channels in 
PASMCs from patients with PH. Thus, a decrease in K
+
 channels gene expression 
and/or function stimulates PASMCs proliferation by increasing [Ca
2+
]cyt and inhibits 
PASMCs apoptosis by decelerating apoptotic volume decrease and attenuating 
cytoplasmic caspase activity. These alterations contribute to the vascular remodeling 
observed in PAH [88]. Tang et al. [89] reported the involvement of TASK-1 (two pore-
related acid-sensitive potassium channel-1) in the ET-1-mediated depolarization in 
human PASMCs. They concluded that ET-1 depolarizes primary human PASMCs by 
phosphorylating (inhibiting) TASK-1. In addition, they presented a mechanism in which 
ET-1 binds to the G protein-coupled receptor ETA, leading to the PKC-induced 
phosphorylation of TASK-1 channels through phospholipase C (PLC), 
phosphatidylinositol 4, 5-biphosphate (PIP2) and diacylglycerol.  
 
2.5.3. Fibroblasts 
 The adventitial compartment, mostly composed by fibroblasts may be 
considered a principal injury-sensing tissue of the vessel wall. In response to 
environmental stresses, such as hypoxia, vascular distention or vascular injury, resident 
fibroblasts are activated and undergo a variety of functional changes [84]. It has been 
reported that fibroblasts are able to (i) proliferate in greater propensity than SMCs in 
response to injury, (ii) differentiate in smooth muscle-like cells (i.e. myofibroblasts), 
which can accumulate in the adventitia and/or migrate to the medial and intimal layers 
of the vessel wall, (iii) increase and alter the profile of extracellular matrix (ECM) 
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deposition, (iv) synthesize and release molecules that act on neighbouring SMCs and 
ECs, and (v) express molecules/receptors that facilitate the recruitment of circulating 
leukocytes to the adventitial compartment [90]. The identification of fibroblasts is a 
difficult task, because markers frequently used, such as vimentin and α-smooth muscle 
actin, lack specificity and sensitivity. Vimentin does not distinguish fibroblasts from 
other cells of mesenchymal origin. α-smooth muscle actin has been used to identify 
myofibroblasts and is not generally observed in resting fibroblasts; in addition, it is 
observed in SMCs and in circulating smooth muscle precursors [90]. Activation of 
fibroblasts results in their differentiation into myofibroblasts. It was observed the 
appearance of myofibroblasts expressing α-smooth muscle actin in the adventitia in 
hypoxia-induced pulmonary hypertension [90]. Myofibroblasts are the principal 
producers of collagen and other extracellular matrix proteins, including fibronectin, 
tenascin-C and elastin. They appear to be capable of migration from the adventitia to the 
media or even to the intima and thus contribute to the thickening of these components 
[90]. Accumulation of myofibroblats in the intima of patients with PH has been 
observed [91]. In addition, it was shown an excessive deposition of ECM proteins in the 
adventitia in PAH. Marked increases in the production and accumulation of collagen 
and elastin were observed in the adventitia during the development of PH. Also, 
increases in the accumulation of fibronectin, tenascin-C and elastin in the adventitia of 
models of hypoxia-induced pulmonary hypertension were observed [90, 92]. Both 
tenascin-C and fibronectin are associated with fibroblast and SMC proliferation and 
have also been shown to contribute to differentiation in a myofibroblast. Fibronectin 
and tenascin-C deposition coincides with the expression and activity of matrix 
metalloproteinases (MMPs), a family of zinc enzymes produced by fibroblasts and 
macrophages responsible for degradation of the ECM components, including collagen,  
fibronectin,  and  various  proteoglycans. These enzymes are also important to smooth 
muscle and endothelial cells migration and proliferation [90]. Excessive or 
inappropriate expression of MMPs may contribute to the pathogenesis of PAH, because 
MMPs may be necessary for the fibroblast to move through the adventitial matrix into 
the media and even intima. MMP activity is upregulated in adventitial fibroblasts from 
animals with hypoxia and monocrotaline-induced pulmonary hypertension [90, 93]. It 
has been reported that inhibition of MMP activity attenuates monocrotaline-induced 
pulmonary hypertension [94].  
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2.5.4. Inflammatory cells 
 There are several observations that argue for the role of inflammation in 
the pathogenesis of PAH. These include the association of PAH with several collagen 
vascular autoimmune disorders (e.g., scleroderma, systemic lupus erythematosus and 
connective disorders) and schistosomiasis; the presence of T cells, B cells and 
macrophages in plexiform lesions; the detection of auto-antibodies to endothelial cells 
and fibroblasts; raised blood cytokine and chemokine levels and the association of PAH 
with certain infections such as human herpes virus 8, human immunodeficiency virus 
and hepatitis C virus [1, 54, 95]. Studies by Austin et al. [96] showed a preponderance  
of CD3+ and CD8+ T-lymphocytes in lungs of PAH patients. Regarding B-cells, it was 
reported the detection of antibodies produced by B-cells against endothelial cells and 
fibroblasts in patients with PAH; in addition, it was also verified the activation of B-
cells in peripheral blood in patients with idiopathic PAH [97-99].  
Regarding the contribution of cytokines and chemokines to the 
development of PAH, patients with idiopathic or associated PAH exhibit higher 
circulating levels and pulmonary expression of interleukin (IL)-1β, IL-6 and TNF-α 
(tumor necrosis factor-α) than healthy individuals [54, 100, 101]. Transgenic mice 
overexpressing IL-6 have been shown to develop spontaneous pulmonary vascular 
remodeling and PH [102]. Also, transgenic mice overexpressing TNF-α develop severe 
PH and right ventricular hypertrophy [103]. 
  The chemokine fractalkine (FKN/CX3CL1) and its receptor (CX3CR1), 
which is expressed by monocytes, mast cells, T cells, natural killer cells and other cell 
types, have been suggested to play important roles in monocyte/T-cell recruitment to the 
vessel wall [54, 104]. Balabanian et al. [105] have shown that CX3CR1 was 
upregulated in circulating T-cells from PAH patients compared to controls, elevated 
FKN plasma concentrations were found in PAH patients compared with controls, and an 
increase in FKN mRNA expression was detected in lung tissue of PAH patients 
compared to controls. They also showed that PAECs from PAH patients expressed 
FKN. In addition, Perros et al. [106] demonstrated that FKN is expressed by 
inflammatory cells surrounding pulmonary arterial lesions and that SMCs from these 
vessels have increased CX3CR1 expression. They also verified that cultured rat 
PASMCs express CX3CR1 and that FKN induces proliferation but not migration of 
these cells. 
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  RANTES (Regulated upon Activation, Normal T-cell Expressed and 
Secreted), also known as CCL5 is another chemoattractant for monocytes and T-cells 
that has been showed to cause an induction of endothelin-converting enzyme-1 and ET-
1 [104]. It has been showed an increased expression of RANTES mRNA in lung 
samples from PAH patients compared with control patients [107]. The authors of this 
study also verified that the major source of RANTES in PAH patients was endothelial 
cells from lung tissue.  
Monocyte chemotactic protein (MCP-1), also known as CCL2 is 
produced by pulmonary vascular cells (SMCs and ECs) and can stimulate 
monocyte/macrophage migration and smooth muscle proliferation [54]. Sanchez et al. 
[108] showed that the levels of CCL2 was elevated in plasma and lung tissue of PAH 
patients, verifying an elevated CCL2 release from pulmonary ECs or SMCs. They also 
verified an enhanced monocyte migration in the presence of pulmonary endothelial cells 
from patients with idiopathic PAH. In addition, compared with controls, PASMCs from 
PAH patients demonstrated stronger proliferative responses to CCL2, in keeping with 
the finding that CCR2 (CCL2 receptor) was markedly increased in PASMCs from these 
patients. Antibodies directed against CCL2 have been shown to attenuate the 
development of PH, reducing infiltration of monocytes into the lung.  
 Stromal cell-derived factor-1α (SDF-1α), also known as CXCL12 is a 
small cytokine belonging to the chemokine family. SDF-1α activates leukocytes, and is 
often induced by proinflammatory stimuli such as lipopolysaccharides, TNF-α and IL-1 
[54]. Young et al. [109] demonstrated that inhibition of the SDF-1α – CXCR4 (SDF-1α 
receptor) axis decreased pulmonary vascular cell proliferation and apoptosis and 
prevented the development of hypoxia-induced pulmonary vascular remodeling in 
neonatal mice.  
It was reported that mast cells are a rich source of IL-4, as well as other 
factors that can stimulate B-cells to secrete auto-antibodies, including anti-endothelial 
cell antibodies; in addition, mast cells degranulation (activation) had been showed to be 
involved in the development of pulmonary vascular remodeling in chronic hypoxic rats 
[54, 110]. Dahal et al. [111] demonstrated that the accumulation and activation of mast 
cells in the lungs contribute to the development of PH in monocrotaline-rats and they 
observed that mast cells population was about 8 fold higher in idiopathic PAH patients 
compared with controls, with the majority of mast cells degranulated. 
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2.5.5. Platelets 
  It has been showed that multiple procoagulant aberrations are present in 
PAH patients, related to endothelial dysfunction, abnormalities of the coagulation 
cascade and disordered platelet function. These include increased levels of von 
Willebrand factor, plasma fibrinopeptide A, PAI-1, 5-HT, and TXA2 and decreased 
levels of t-PA, thrombomodulin, NO, and PGI2 [112]. Platelets not only participate in 
clot formation, but also are capable of releasing many vasoactive substances that 
promote vasoconstriction, as well as growth factors that stimulate proliferation of 
smooth muscle cells, endothelial cells, and fibroblasts [71]. One of the most important 
mediators released by platelets is serotonin. 
Serotonin is produced by the gastrointestinal tract enterochromaffin cells 
and pulmonary neuroepithelial bodies and stored in platelets (the major repository of 5-
HT) [26]. Circulating 5-HT levels are normally low, since free 5-HT is taken up for 
storage in platelets via the 5-HT transporter (5-HTT or SERT), or is metabolized in the 
liver [29]. 5-HT is also taken up by the 5-HTT in neurons, pulmonary artery smooth 
muscle and endothelial cells. Pulmonary artery endothelial and smooth muscle cells also 
express 5-HT1B, 5-HT2A and 5-HT2B receptors, which are G protein coupled receptors 
[34]. Serotonin is a vasoconstrictor that stimulates the proliferation of SMCs and 
fibroblasts [34, 35]. A significant rise of 5-HT in plasma is seen in pulmonary 
hypertensive patients and the level in platelets is low [36]. Activation of serotonin 
receptors 5-HT1B, 5-HT2A, and 5-HT2B causes vasoconstriction, although 5-HT2B is also 
implicated in the mitogenic action of 5-HT. The signaling pathways include mediators 
such as adenylate cyclase and PKA [34]. Mice deficient in 5-HT1B receptors show 
reduced pulmonary vascular remodeling and absence of right ventricular hypertrophy on 
exposure to hypoxia [113]. Specific 5-HT2A receptor blockade inhibits the development 
of PH in rats injected with monocrotaline and improves survival [114]. Human studies 
suggest that 5-HT mediates vasoconstrictive effects mainly by the 5-HT1B receptor, 
which explains why a 5-HT2A receptor antagonist has had only limited effect in the 
treatment of PAH [115, 116]. 5-HTT is encoded by a single gene on chromosome 
17q11.2, and a variant in the upstream promoter region of this gene has been described. 
There are two polymorphic forms: the long (L) and the short (S). These polymorphisms 
affect 5-HTT expression and function with the L-allele inducing a greater rate of 5-HTT 
gene transcription than the S-allele. Isolated PASMCs expressing the LL genotype took 
up more 5-HT and had increased growth versus cells that were heterozygous (LS) or 
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homozygous for the short variant. The L-allelic variant was found to be present in 
homozygous forms in 65% of idiopathic PAH patients, but only in 27% of controls 
[117]. In experimental models, there is attenuated severity of pulmonary vascular 
disease in mice lacking the gene encoding the 5-HTT [118]. In contrast, overexpression 
of the serotonin transporter in a transgenic mouse worsens hypoxia-induced PAH [119]. 
 
2.6. Experimental models  
 Animal models have allowed the study of the pathogenesis of PAH, as well as 
the effects of drug intervention. An animal model should mimic the human disease and 
allows determination of relevant clinical, biochemical, hemodynamic and 
histopathological features. However, no model mimics exactly all the features of the 
human disease [120, 121] and thus, caution must be taken when extrapolating data 
obtained from animal models to human pathophysiology. As human PAH has many 
genetic and environmental causes, it may be appropriate to study different animal 
models to better understand the disease [120]. The most commonly used animal models 
of PAH are the monocrotaline model and the chronic hypoxic model [122]. Chronic 
hypoxia can be induced by exposing animals to normal air at hypobaric pressures or to 
oxygen-poor air at normal pressure [123]. This decrease in oxygen pressure elicits a 
strong pulmonary vasoconstrictor response [124]. Recently, Taraseviciene-Stewart and 
colleagues [125] described a rat animal model of PAH that involves a combination of 
vascular endothelial growth factor receptor blockade with SU5416 and chronic hypoxia 
exposure, demonstrating a severe pulmonary hypertension associated with precapillary 
arterial occlusion by proliferating endothelial cells. In addition, new animal models of 
PAH involve the use of genetically modified animals, since various mutations have 
been shown to be implicated in the development of PAH [124]. An example is the use 
of genetically engineered mouse overexpressing 5-HTT [119]. It follows a more 
detailed description of the features of the monocrotaline model, an animal model that 
has been used for over 40 years [126, 127]. 
 
2.6.1. Monocrotaline model 
 Monocrotaline (MCT) is a pyrrolizidine alkaloid present in the stems, 
leaves, and seeds of the Crotalaria spectabilis and in all the other plants of the 
Crotalaria genus, but in a lesser concentration. The toxicity of MCT is essentially 
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hepatic and cardiopulmonary, affecting both animals and humans. However, if applied 
topically or injected it does not cause localized toxicity. MCT will cause lesions in 
several organs after absorption and hepatic bioactivation [128]. Within the liver, MCT 
may undergo several chemical reactions, leading to toxic and non toxic products. 
Monocrotaline pyrrole (MCTP), also called dehydromonocrotaline, is a toxic metabolite 
of MCT formed by the cytochrome P450 3A in the liver [129]. 
 Clinical signs of illness are usually not evident immediately after a single 
exposure of rats to doses of MCT that result in pulmonary hypertension. Within 3-7 
days, rats show anorexia, listlessness, failure to gain weight and tachypnea. As lung 
injury and vascular remodeling progress, animals develop variable degrees of dyspnea, 
weakness, diarrhea, and peripheral cyanosis [127].  
 The pulmonary vascular endothelium is thought to be the early target of 
MCT intoxication based on circulatory proximity to the liver [130]. It was verified that 
hypertrophy and increased DNA synthesis in endothelial cells occur within 7-14 days 
after MCT (P) treatment [131, 132]. The term “megalocytosis”, which refers to enlarged 
cells with enlarged nuclei, reflects this phenotypic change caused by pyrrolizidine 
alkaloids [133]. In addition, intoxication with monocrotaline is associated with 
increased intimal expression of endothelin-1 [134], while the expressions of the ETB 
and eNOS are decreased [135, 136]. Changes in the medial layer due to C. spectabilis or 
MCT (P) administration occur after intimal changes and are characterized by increased 
DNA synthesis, hypertrophy and hyperplasia of smooth muscle and extension of 
smooth muscle to normally non muscular pulmonary arteries [128, 137]. The medial 
expressions of the serotonin transporter and survivin, an inhibitor of apoptosis, are 
increased [4, 138], while there is a decreased expression of voltage-gated potassium 
channels, including Kv1.5 and Kv2.1 [73]. Also, the expression of BMPRII is 
decreased, but its restoration does not improve pulmonary hypertension [139]. Lesions 
of the adventitia caused by administration of MCT (P) or C. spectabilis to rats are 
initially characterized by the infiltration of inflammatory cells [128]. Lungs from 
monocrotaline-intoxicated rats present increased expression of several pro-
inflammatory cytokines such as IL-1β, IL-6, MCP-1, ICAM-1 (intracellular adhesion 
molecule-1), E-selectin, and TGF-β. In addition, there is an adventitial increased 
production of extracellular matrix glycoproteins, like elastin, fibronectin, collagen, and 
tenascin-C [136, 140].  
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 Rats chronically exposed to MCT in drinking water or food develop right 
cardioventricular hypertrophy [141]. Kay et al. [126] also demonstrated that the oral 
administration of Crotalaria spectabilis seeds to young rats induces pulmonary 
hypertension associated with right ventricular hypertrophy. In addition, administration 
of MCT 60 mg/ kg sc (subcutaneous) to rats results in right ventricle hypertrophy [142]. 
The macroscopic evidence of right heart enlargement is accompanied by an increased 
rate of ventricular protein synthesis [141]. It was observed marked increases in both 
cross-sectional area and cell length in myocytes from the right ventricle of rats treated 
with MCT. There is general agreement that the cardiac lesions occur as a physiologic 
response to an increased workload that results from a sustained elevation in pulmonary 
arterial pressure. Hypertrophy has not been reported in the left ventricle [128, 142]. In 
monocrotaline-induced pulmonary hypertension it was also shown a twofold increase in 
the Fulton index (ratio of right ventricular free wall weight divided by the sum of the 
septum plus left ventricular free wall weight). Regarding the hepatic lesions, animals 
intoxicated with monocrotaline present with hepatic necrotic lesions and cirrhosis [136]. 
Monocrotaline-induced pulmonary hypertension is similar to PAH in 
terms of hemodynamic and histopathological severity and high mortality. However, it 
differs from PAH by an initial permeability lung edema, with early loss of the 
endothelial barrier and striking inflammatory adventitial proliferation [136]. In addition, 
in PAH it is verified plexiform lesions, which are not observed in monocrotaline-
induced pulmonary hypertension [122]. However, it has been reported the development 
of plexiform lesions in a rat model (rats with approximately 6 week old) that combined 
treatment with MCT and partial pneumonectomy [143]. A limitation of MCT model is 
that differences exist in monocrotaline sensitivity between rat strains as well as 
individual variances in the pharmacokinetics of monocrotaline involving degradation 
and hepatic formation of the pyrrole or conjugation and excretion [124]. However, the 
monocrotaline rat model continues to be a frequently used model of PAH as it offers 
technical simplicity, reproducibility and low cost compared to other models of PAH 
[144]. 
 
2.7. Diagnosis and prognosis 
 In the presence of a suspected PAH patient, multiple exams are required to 
confirm the diagnosis, clarify the specific etiology within the PAH group and also 
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evaluate the functional and hemodynamic impairment. Importantly, the diagnosis of 
PAH, and particularly of idiopathic PAH is a diagnosis of exclusion [145].  
 Regarding the clinical presentation, the symptoms of PAH are non-specific and 
include breathlessness, fatigue, weakness, angina, syncope, and abdominal distension. 
Symptoms at rest are reported only in advanced cases. The signs of PAH include RV 
third sound, tricuspid insufficiency murmur, prominent right ventricular impulse and 
accentuated pulmonic valve component. Jugular vein distention, hepatomegaly, 
peripheral edema, ascites and cool extremities can be present in a more advanced state 
of the disease [145, 146].  
The electrocardiogram (ECG) may provide evidence of PH by demonstrating 
RV hypertrophy, and right atrial dilatation. RV hypertrophy on ECG is present in 87% 
and right axis dilatation in 79% of patients with idiopathic PAH. The absence of these 
findings does not exclude the presence of PH nor does it exclude severe haemodynamic 
abnormalities [145]. In 90% of patients with idiopathic PAH the chest radiography is 
abnormal at the time of diagnosis. Findings include central pulmonary arterial 
dilatation, which contrasts with loss of peripheral blood vessels. Right atrium and RV 
enlargement may be seen in more advanced cases [145]. Pulmonary function and 
arterial blood gases tests are also realized. Arterial blood gas analysis may help to 
exclude hypoxia as a contributor to pulmonary hypertension [146]. Pulmonary function 
tests are necessary to establish airflow obstruction or restrictive pulmonary pathology 
[146]. Transthoracic echocardiography provides several variables which correlate with 
right heart haemodynamics including PAP, and should always be performed in the case 
of suspected PH [145]. High-resolution computed tomography provides detailed views 
of the lung parenchyma and facilitates the diagnosis of interstitial lung disease and 
emphysema [145]. Cardiac magnetic resonance imaging provides a direct evaluation of 
RV size, morphology, and function and allows non-invasive assessment of blood flow 
including stroke volume, cardiac output, distensibility of pulmonary artery and RV mass 
[145]. Abdominal ultrasound should be used to exclude liver cirrhosis and/or portal 
hypertension [145]. 
In all the patients should be performed routine biochemistry, haematology and 
thyroid function tests. Serological testing is important to detect connective tissue 
diseases, HIV and hepatitis [145, 146]. Up to 2% of individuals with liver disease will 
manifest PAH and therefore liver function tests and hepatitis serology should be 
examined. Thyroid disease is commonly seen in PAH and should always be considered 
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[145]. A range of biomarkers have been described in PAH, which may be of diagnostic 
and prognostic significance. These include markers of heart failure, endothelial and/or 
platelet dysfunction and cardiac myocyte damage [147]. Examples are atrial natriuretic 
peptide (ANP) and brain natriuretic peptide (BNP). More recently, interest has turned to 
the N-terminal fragment of BNP (NT-proBNP) as an alternative biomarker to BNP, 
because it seems to provide the same information, but has advantages in terms of 
stability. Another biomarkers used are ET-1, acid uric, troponin T, NO, cGMP, D-
dimer, von Willebrand factor and 5-HT [147].  
Cardiac catheterization should be performed in patients with unexplained 
pulmonary hypertension, and remains the gold standard for PH diagnosis and 
quantification [146]. The following variables must be recorded during right heart 
catheterization (RHC): PAP (systolic, diastolic, and mean), right atrial pressure, PWP 
(pulmonary wedge pressure), and RV pressure. In PAH, vasoreactivity testing should be 
performed at the time of diagnostic RHC to identify patients who may benefit from 
long-term therapy with calcium channel blockers (CCBs). This test should only be 
performed with short-acting, safe, and easy to administer drugs with no or limited 
systemic effects. Currently the agent most used in acute vasodilator testing is NO; 
intravenous epoprostenol or intravenous adenosine may also be used as an alternative 
(but with a risk of systemic vasodilator effects). Only the patients that respond 
positively to these testing drugs can safely be treated with CCBs [145].  
Assessment of functional exercise is needed to evaluate disease severity. Two 
commonly used tests are the 6 minute walk test (6MWT) and the cardiopulmonary 
exercise testing [148]. 
Thus, the knowledge of the clinical history of the patient and a careful physical 
examination are paramount to the diagnosis of pulmonary hypertension. Particular 
attention should be given to previous medical conditions, drug use and family history. 
In addition, all systems should be carefully reviewed [146]. Importantly, survival after 
diagnosis is estimated as low as 2.8 years, if left untreated and death occurs, in most 
cases, from right ventricular failure [7, 146].  
 
2.8. Treatment  
The knowledge of the etiology of the disease provides the basis for the 
pharmacological approach. However, since PAH appears to have a multi-factorial 
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nature, the treatment has remained primarily palliative till recently. With the advances 
in the knowledge of the pathogenesis of PAH over the last years, the treatment of this 
disease has improved significantly [148], emerging treatments that target the pathways 
underlying the development of PAH. However, these treatments may slow the 
progression of the disease but not afford a cure [149]. In table 3, it follows a description 
of some current therapies in PAH grouped according to the target pathway. 
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Table 3 – Current therapies for pulmonary arterial hypertension. 
 
Drug Route Adverse effects and 
contraindications 
Comments and 
recommendations 
References 
Supportive therapies 
Anticoagulants  O Bleeding  [150, 151] 
Diuretics  O Hypotension Used to reduce fluid retention [152] 
Oxygen In  Useful in patients with 
hypoxia 
[152, 153] 
Digoxin O Arrhythmias, vomiting Modest benefit on right 
ventricular function 
[152, 154] 
Inotropes  IV Tachycardia Mostly used in patients with 
end-stage right heart failure  
[152] 
Calcium-channel blockers 
Nifedipine O Hypotension, peripheral 
edema 
Favorable as long-term 
treatment in patients with 
acute vasodilator 
responsiveness 
 [152, 155, 
156] Diltiazem O 
Amlodipine O 
Synthetic prostacyclin and prostacyclin analogues 
Epoprostenol cIV Jaw pain, headache, 
flushing, nausea, diarrhea, 
catheter-related sepsis 
Beneficial effects can be 
sustained for years 
[157-159] 
Treprostinil SC Rash, infusion site pain, 
headache, diarrhea, nausea 
 [160, 161] 
Beraprost O Headache, flushing Only modest benefit in the 
short term 
[162, 163]  
Iloprost In Cough, flushing, headache, 
jaw pain,  
  [164] 
Endothelin-1 receptor antagonists 
Bosentan O Hepatotoxicity, headache Dual ETA/ETB antagonist, 
increasingly used as a first-
line drug 
[165-167]  
Sitaxsentan O Hepatotoxicity, warfarin 
interaction 
ETA >> ETB antagonist [168, 169]  
Ambrisentan O Flushing, hepatotoxicity ETA >ETB antagonist [170, 171]  
Type 5 phosphodiesterase inhibitors 
Sildenafil O Headache, nasal 
congestion, visual 
disturbances 
Increasingly used as a initial 
agent as well as  in 
combination therapy  
[172-175] 
Tadalafil O Headache, nausea, dyspnea  [176] 
Interventional procedures 
Atrial 
septostomy 
  Decompresses right heart and 
improves systemic output 
[177] 
Lung 
transplantation 
  Improves survival 
Legend: cIV, continuous intravenous; In, inhaled; IV, intravenous; O, oral; SC, subcutaneous.  
 
Current treatments include supportive therapies, calcium channel blockers, 
synthetic prostacyclin and prostacyclin analogues, endothelin-1 receptor antagonists, 
type 5 phosphodiesterase inhibitors and interventional procedures. Supportive therapies 
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are adapted from other diseases with similar symptoms of PAH and have the aim of 
relief the symptoms. As discussed in the section 2.7., patients who may benefit from 
long-term therapy with CCBs are identified by their initial response to a vasodilator 
challenge. The patient could benefit from CCBs therapy if their response is positive. A 
response is considered positive if there is a decrease of at least 10 mmHg in the mean 
PAP, to a value of less than 40 mmHg with an increased or unchanged cardiac output. 
Importantly, only approximately 10-15% of patients with idiopathic PAH will meet the 
criteria for a positive response [145, 178]. Prostacyclin analogues, ET-1 receptor 
antagonists and type 5 phosphodiesterase inhibitors act primarily with the aim of 
improve vasodilatation.  
Regarding surgical procedures, lung and heart/lung transplantation as well as 
atrial septostomy have been available for years to treat severe PAH. However, with the 
development of pharmacologic therapy, the need for these interventions has diminished, 
remaining the treatment of last resort, being used in patients who fail to respond 
favorably to pharmacologic therapy [179]. 
3. Survivin: a new target for PAH treatment 
The therapies mentioned in the previous section, which focus in the promotion of 
vasodilatation, are not sufficient to offer a cure to PAH. Thus, more research is needed 
to find more therapeutic targets aiming effective treatments. There is an increasing 
interest in the last years to target the proliferative and apoptotic pathways, instead of 
vasoconstriction [180-182]. In this context, survivin, a molecule that performs functions 
both in cellular proliferation and apoptosis is a promising target [5, 183].  
Survivin, a protein discovered in 1997 in human B-cell lymphoma, is the smallest 
element of the inhibitor of apoptosis (IAP) family, with 142 amino acids and 16.5 kDa 
[5, 183, 184]. The IAP proteins identified in humans include X-chromosome-linked IAP 
(XIAP), cellular inhibitor of apoptosis 1 and 2 (cIAP1, cIAP2), neuronal apoptosis 
inhibitor protein (NAIP), IAP-like protein 2, livin, BRUCE and survivin [183]. All IAP 
family members share two to three common structures of baculovirus IAP repeat (BIR) 
domains, containing 70-80 amino acids and localized at the N-terminus region, 
responsible for bind and inactivate caspases. However, survivin only contains a single 
BIR domain that stretches from amino acid residue 15 to 87. Most of IAPs, excluding 
survivin, possess other domains such as a carboxyl-terminal RING (really interesting 
new gene) domain, important for ubiquitination and proteossomal degradation of 
 27 
 
caspases [183, 185, 186]. Alternative splicing of survivin pre-mRNA from chromosome 
17q25 produces five different mRNAs, which encode five distinct proteins, survivin, 
survivin 2B, survivin ∆Ex3, survivin 3B and survivin 2α. These survivin isoforms differ 
both in intracellular localization and in their ability to inhibit apoptosis [5, 183, 187]. 
Survivin plays a critical role in the regulation of cell division and viability. It has 
been reported that disruption of survivin locus in mice results in early embryonic 
lethality and loss of tissue viability [183, 188, 189]. Survivin shows a cell-cycle 
dependent expression at mitosis. There is an upregulation of survivin during the G2/M 
phase of the cell cycle. During mitosis, survivin exists as a multi-protein complex, 
known as the chromosomal passenger complex (CPC), and localizes to different 
components of the mitotic apparatus, including centromeres in prophase, kinetochores 
of the metaphase and anaphase spindle, and the midbody during cytokinesis [5, 183, 
187, 188]. For these survivin functions on mitosis, it is crucial that a phosphorylation by 
cdc2, a mitotic kinase, on threonine 34 of survivin occurs. It has been reported that 
inhibition of survivin expression/function results in multiple mitotic defects, including 
cell cycle arrest at prometaphase, appearance of aberrant spindles, cytokinesis failure, 
and generation of multinucleated polyploidy cells. This reflects the important roles of 
survivin in multiple phases of mitosis [188].  
Regarding the role of survivin in apoptosis, it was reported that in response to cell 
death stimulation, mitochondrial survivin is released to cytosol, where it prevents 
caspase activation and inhibits apoptosis [5, 183, 188, 190]. Transgenic animals 
expressing survivin are protected against apoptosis, in vivo, and molecular antagonists 
of survivin, such as, ribozymes, RNA interference, and dominant-negative mutants 
cause caspase-dependent cell death and enhance apoptosis [188]. The BIR2 domain of 
IAPs is capable of bind and inhibits caspases-3 and -7, whereas BIR3 is an inhibitory 
segment for caspase-9. BIR1 is not known to possess the inhibitory ability of caspase 
activation. The only BIR domain of survivin appears closely related in the structure to 
the BIR3 domain of XIAP, suggesting that survivin binds and inhibits caspase-9 [191]. 
Although some authors reported that survivin can directly bind and inhibit caspase -3, -
7 and -9 activity, Song et al. [192] showed that survivin does not interact physically 
with caspases, but inhibits apoptosis through the interaction with Smac, in apoptosis 
induced by Taxol (a potent anti-tumor drug). Smac promotes caspase activation by 
binding and inhibiting IAPs activity. They proposed that during apoptosis survivin 
binds to Smac released from the mitochondria, thus reducing antagonism of Smac to 
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XIAP, and the free XIAP directly interacts with caspases, blocking cell death. This 
mechanism suggests that the anti-apoptotic effect of survivin may be mitochondria-
dependent, because Smac is released from mitochondria. Survivin can also have other 
anti-apoptotic mechanisms. It has been reported that in response to cell death 
stimulation, survivin interacts with XIAP, and this complex increases XIAP stability 
against polyubiquitination and proteasomal degradation, enhancing its anti-caspase 
activity [193].  
Regarding the use of survivin as a therapeutic target in PAH, there is not much 
information. McMurtry et al. [4], in addition to show that this pathway is up-regulated 
in patients with PAH and in rats injected with MCT, comparing with controls, they 
showed that inhaled adenoviral gene therapy with a survivin mutant (Thr34Ala) 
reverses MCT-PAH. They also reported that both in vitro and in vivo survivin targeting 
induces PASMCs mitochondria-dependent apoptosis and is associated with activation of 
potassium channels. An alternative to gene therapy is follows a pharmacological 
approach. In this context, terameprocol can be a promising option. Terameprocol (meso-
tetra-O-methyl nordihydroguaiaretic acid, TMP) is a methylated derivate of 
nordihydroguaiaretic acid, found in the plant Larrea tridentate, reported to block cell 
cycle progression by inhibiting expression of the Sp1-dependent gene coding for cdc2 
and promotes apoptosis by inhibiting expression of the survivin gene, whose expression 
is also highly dependent of the transcription factor Sp1 [6, 194]. This compound inhibits 
the growth of tumors by targeting cdc2 and survivin. Currently, trials are ongoing in 
patients with some cancer types [5, 183]. As cancer, PAH is characterized by an 
excessive proliferation and reduced apoptosis, which contributes to the vascular 
remodeling characteristic of this disease and thus, TMP can be a promising therapy and 
its effects in PAH should be evaluated. 
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4. Aims  
Given the importance of the vascular remodeling in the progression of PAH, 
characterized by an excessive cellular proliferation and a decreased apoptosis, the aim 
of the present work was to evaluate the effects of terameprocol, a pro-apoptotic and 
anti-proliferative drug, in the proliferation and apoptosis of PASMCs in PAH. To 
achieve this goal, we evaluated the effect of the addition of different concentrations of 
terameprocol in the cellular proliferation and apoptosis in SMCs primary cultures 
isolated from animals injected with MCT. 
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5. Materials and methods 
 
5.1. Experimental Design 
The experimental design is summarized in figure 3.  
 
 
 
Figure 3 – Experimental protocol design (ip, intraperitoneal). 
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5.2. Animal and Experimental Protocol 
Animal experiments were performed according to the Portuguese law for 
animal welfare and conform to the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals (NIH Pub. Nº 85-23, Revised 1996). Adult male Wistar rats 
(Charles River Laboratories; Barcelona, Spain) weighing 180–200 g were housed in a 
controlled environment under a 12:12 h light-dark cycle at a room temperature of 22ºC, 
with a free supply of food and water. Rats were randomly divided in two groups, one of 
which received a subcutaneous injection of MCT (60 mg/kg body weight; Sigma, 
Barcelona, Spain) (monocrotaline group) and the other an equal volume of vehicle 
(NaCl 0.9%; 2 ml/kg body weight) (sham group).  
5.3. Hemodynamic evaluation 
On day 21 after MCT/vehicle injection, 7-12 rats per group were anesthetized by 
inhalation of a mixture of sevoflurane (4 %) and oxygen, intubated for mechanical 
ventilation, and placed over a heating pad. Under binocular surgical microscopy (Wild 
M651.MS-D; Leica), the right jugular vein was cannulated for fluid administration 
(prewarmed 0.9 % NaCl solution) to compensate for perioperative losses. The heart was 
exposed through a median sternotomy, and the pericardium was widely opened. A 
pressure-volume (PV) catheter was implanted in the RV (PVR-1045, Millar 
Instruments, Houston, TX). After complete instrumentation, the animal preparation was 
allowed to stabilize for 15 minutes. Hemodynamic recordings were made under basal 
conditions with respiration suspended at end-expiration. Data was continuously 
acquired (MPVS 300, Millar Instruments), digitally recorded at 1000 Hz (ML880 
PowerLab 16/30, Millar TM Instruments), and analyzed (PVAN 3.5, Millar 
Instruments). RV pressure was measured at peak systole (Pmax).  
5.4. Morphometric analysis 
After hemodynamic assessment, animals were euthanized by exsanguination 
under anesthesia. The heart and lungs were excised and weighed. The RV free wall was 
dissected from the left ventricle (LV) + septum (S), under binocular magnification 
(x3.5), and weighed separately. Heart, lungs and RV weights were normalized to body 
weight (BW). RV weight was also normalized to that of LV + S. RV and right lung 
samples were immersion fixed in 4 % paraformaldehyde and embebbed in paraffin. 
Sections 4 μm thick were cut and stained with hematoxylin and eosin. RV free wall 
specimens were obtained from each heart at midway between the apex and base. 
 32 
 
Studied samples were observed at microscope, photographed with a digital camera and 
measured with a digital image analyzer (cell^B life science basic imaging software, 
Olympus). All the measures were made directly at 400x magnification. RV samples 
were divided into five sections and the area of fifty cardiomyocyte (whose cross section 
included a nuclear profile) per sample was measured and averaged. On the pulmonary 
specimens, external diameter and medial wall thickness in muscular arteries (12-18 
arteries/lung) were analyzed at 400x magnification. Orthogonal intercepts were used to 
generate eight random measurements of external diameter (distance between the 
external lamina) and sixteen random measurements of medial thickness (distance 
between the internal and external lamina). For each artery, medial hypertrophy was 
expressed as follows: % wall thickness = [(medial thickness x 2)/ (external diameter)] x 
100.  
5.5. Isolation and primary culture of rat pulmonary artery smooth muscle cells 
Animals assigned to the cell culture protocol were euthanized with an 
intraperitoneal injection of pentobarbital (120 mg/kg) (n=3 per group), 21 days after 
MCT/vehicle injection. The heart and lungs were removed en bloc and the left upper 
lung lobe was removed and placed in a calcium enriched Hank´s Buffered Salt Solution 
(HBSS, Invitrogen, Madrid, Spain) (mM: KCl 5.4; NaCl 137; KH2PO4 0.44; NaHCO3 
4.2; NaH2PO4 0.25; D-glucose 1; phenol red 0.2; CaCl2 2 and MgCl2 1). First order 
intrapulmonary artery was dissected under a stereomicroscope (Leica EZ4), in sterile 
conditions. After the artery was extracted from the lung, the adventitia was removed, the 
vessel was opened longitudinally and endothelium was removed by gently rubbing the 
inner surface with forceps tips. The artery, now mainly composed by medial layer, was 
submitted to an enzymatic dissociation process with papain (Sigma, Barcelona, Spain) 
and collagenase type 1 (Worthington Biochemical Corp., Lakewood, New Jersey), in a 
calcium-poor HBSS solution (25 μM CaCl2 and 1 mg/mL BSA), with the aim to release 
smooth muscle cells. Then, a mechanical dissociation process was performed with a fire 
polished, silicone coated glass pipette, to release the cells. The cell-free tissue was 
removed and the solution was centrifuged (5 minutes, 250 g) to pellet the cells. Finally, 
cells were seeded in DMEM (PAN Biotech, Aidenbach, Germany) culture medium, 
supplemented with 1 % penicillin-streptomycin-amphotericin B (Invitrogen, Madrid, 
Spain), 1 % sodium pyruvate (Sigma, Barcelona, Spain) and 1 % nonessential amino 
acids (Sigma, Barcelona, Spain) and containing 10 % FBS (fetal bovine serum, Sigma, 
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Barcelona, Spain), in a 24-well culture plate (500 μL/well) and placed in an incubator 
(37 ºC, 5 % CO2). The medium was changed after 24 h and then every 48 h. Cells were 
subcultured at 70-80 % confluence and they were then detached with trypsin (PAN 
Biotech, Aidenbach, Germany), passaged and cultured continuously. Cells between 
passages 2 and 4 were used for assays. Smooth muscle origin was confirmed by typical 
morphology (fusiform shape with hills and valleys) and detection of α-smooth muscle 
actin expression by immunocytochemistry (data not shown). 
5.6. Assessment of pulmonary artery smooth muscle cell proliferation by BrdU 
assay 
For BrdU assay, cells were seeded in 24-well plates at a concentration of 3x10
4 
cells/mL. After 72 h, the medium was removed and cells were incubated with different 
concentrations of terameprocol (Sigma, Barcelona, Spain) (μM: 0.1; 1; 10; 20 and 50) 
or DMSO (dimethylsulfoxide, Sigma, Barcelona, Spain) (vehicle) for 24 h in medium 
without FBS. The effect of terameprocol in cell proliferation was evaluated using the 5’-
bromodeoxyuridine (BrdU) immunoassay (Roche Diagnostics). BrdU is a thymidine 
analogue and its incorporation in the DNA is a measure of cell proliferation. The BrdU 
assay was conducted following the 24 h incubation with terameprocol/vehicle. All 
protocol was followed according to manufacturer´s instructions. Each condition 
(concentration) was tested in triplicate and in cells from three animals per group. 
Results are expressed as percentage of control (medium with vehicle).  
5.7. Assessment of pulmonary artery smooth muscle cell death by TUNEL 
assay 
For TUNEL assay, cells were seeded in 24-well plates, with glass coverslips, at 
a concentration of 3x10
4 
cells/mL. After 72 h, the medium was removed and cells were 
incubated with different concentrations of terameprocol (μM: 0.1; 1; 10; 20 and 50) or 
DMSO (vehicle) for 24 h in medium without FBS. TUNEL (TdT-mediated dUTP Nick 
End Labelling) assay was performed using the In Situ Cell Death Detection kit (Roche 
Diagnostics), according to the manufacturer’s instructions. After the 24 h incubation of 
cells with terameprocol/vehicle, cells were stained with TUNEL and DAPI. The 
percentage of apoptotic cells was calculated by dividing the number of cells stained 
with TUNEL (apoptotic cells) by the total number of nuclei stained with DAPI (Roche 
Diagnostics), in at least 10 different fields at 200x magnification. Each condition 
(concentration) was tested in triplicate and in cells from three animals per group.  
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5.8. Chronic assessment of pulmonary artery smooth muscle cell proliferation 
by trypan blue exclusion  
Cells were seeded in 24-well plates at a concentration of 3x10
4 
cells/mL. The 
medium was replaced after 24 h and then every 48 h by a medium containing 10% FBS 
and terameprocol (μM: 20 and 50) or DMSO (vehicle). Cellular proliferation was 
evaluated by the performance of growth curves, through the diary counting of cells 
(during 6 days) in a hemocytometer, with exclusion by trypan blue. For each condition 
(concentration) cells from three wells were counted per day and it was used cells from 
three animals per group. 
5.9. Statistical Analysis 
Statistical analysis was performed using Sigma Stat 3.5 software. Values are 
presented as means ± standard error (SE) and were compared using two-way ANOVA. 
When the normality test failed, the two-way ANOVA was preceded by a logarithmic 
transform to obtain a normal distribution. When treatments were significantly different, 
the Holm-Sidak test was selected to perform pairwise multiple comparisons. A p value 
less than 0.05 was considered statistically significant. 
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6. Results 
 
6.1. Characterization of monocrotaline – induced pulmonary arterial 
hypertension animal model 
In order to characterize the animal model of MCT – induced pulmonary arterial 
hypertension from where smooth muscle cells were isolated, we performed a protocol to 
evaluate the hemodynamic and morphometric alterations. Results are showed in table 4 
and figure 4. 
 
Table 4 – Hemodynamic evaluation and morphometric analysis of monocrotaline-induced pulmonary 
arterial hypertension.  
 
Hemodynamic 
evaluation 
Morphometric analysis 
RVPSP (mmHg) BW (g) HT/BW (g/Kg) RV/(LV + S) (g/g) RV/BW (g/Kg) L/BW (g/Kg) 
SHAM MCT SHAM MCT SHAM MCT SHAM MCT SHAM MCT SHAM MCT 
26.3 ± 
1.2 
38.9 ± 
2.7* 
290.6 
± 4.5 
260.8 ± 
4.9* 
2.794 ± 
0.069 
3.282 ± 
0.113* 
0.302 ± 
0.012 
0.467 ± 
0.049* 
0.584 ± 
0.013 
0.911 ± 
0.095* 
4.782 ± 
0.323 
7.241 ± 
0.464* 
 
Data are given as means ± SE. SHAM, sham group; MCT, monocrotaline group; RVPSP, right 
ventricular peak systolic pressure; RV, right ventricle; LS + S, left ventricle plus septum; HT, heart; BW, 
body weight, L, lung. *p < 0.05 vs. SHAM. 
 
As showed in table 4, 21 days after MCT/vehicle injection, MCT group presented a 
significantly higher right ventricular systolic pressure comparing with SHAM group 
(P<0.05), confirming that MCT was effective in inducing the increase in overload. In 
addition, table 4 summarizes morphometric analysis of MCT-induced PAH. MCT group 
presented a significantly lower body weight, on day 21 after injection, comparing with 
animals from the SHAM group (P<0.05). The ratio HT/BW was significantly higher in 
the MCT group (P<0.05). In addition, RV/ (LS + S) and RV/BW indexes were 
significantly higher in the MCT group, indicating the development of RV hypertrophy. 
The parameter L/BW was also significantly higher in the MCT group, comparing with 
SHAM group. 
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Figure 4 – Right ventricular cardiomyocyte cross-sectional area and pulmonary arterial wall thickness 
measurement (A and C, respectively) and right ventricular cardiomyocyte and pulmonary arterial wall 
hypertrophy assessed by microscopic observation (B and D, respectively). SHAM, sham group; MCT, 
monocrotaline group. Data are given as means ± SE. #p < 0.05 vs. SHAM. 
 
Representative examples of right ventricle cardiomyocytes from rats 21 days after 
injection with vehicle and MCT are showed in figure 4B. As depicted in the graphic 
(Figure 4A), cardiomyocytes from MCT group had a significantly higher cross-sectional 
area comparing with SHAM group (P<0.05). Representative examples of morphology 
of pulmonary arteries from rats 21 days after injection with vehicle and MCT are 
showed in figure 4D. Measurement of pulmonary arterial wall thickness revealed 
increased pulmonary arterial wall thickness in MCT-treated groups in comparison to 
SHAM group (P<0.05) (Figure 4C). 
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6.2. Proliferation of pulmonary artery smooth muscle cells – acute studies 
With the aim to evaluate the effect of terameprocol in the proliferation of 
smooth muscle cells primary cultures, isolated from rats with PAH induced by MCT, 
we performed the BrdU assay. The results are shown in figure 5. 
 
 
Figure 5 – Effect of terameprocol in pulmonary artery smooth muscle cell proliferation, evaluated by the 
BrdU assay. SHAM, sham group; MCT, monocrotaline group. Data are expressed as percentage of the 
absorbance of control (TMP 0 μM) from the same group, and given as means ± SE. *p < 0.05 vs. control 
of the same group; #p < 0.05 vs. SHAM of the same TMP concentration; 
b
p < 0.05 vs. 10 μM of the same 
group; 
c
p < 0.05 vs. 1 μM of the same group; dp < 0.05 vs. 0.1 μM of the same group. 
 
The results showed that the pattern of proliferation did not differ between the SHAM 
and the MCT groups. In addition, for the higher concentrations that were tested (10, 20 
and 50 μM), terameprocol significantly inhibited cell proliferation, in a dose-dependent 
manner, in both SHAM and MCT groups. However, the inhibition of proliferation, 
using the lower terameprocol concentrations (0.1 and 1 μM) did not differ from the 
control (TMP 0 μM). For some terameprocol doses (0.1, 20 and 50 μM) it was verified a 
less marked inhibition of the proliferation of cells treated with MCT, comparing with 
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the cells treated with vehicle, being this result statistically significant for the TMP 
concentration of 20 μM. 
 
6.3. Evaluation of pulmonary artery smooth muscle cell apoptosis 
To evaluate the effect of terameprocol in the apoptosis of smooth muscle cells 
primary cultures, isolated from rats with PAH induced by monocrotaline, we performed 
the TUNEL assay. Results are plotted in figure 6. 
 
 
Figure 6 – Effect of terameprocol in pulmonary artery smooth muscle cell apoptosis, evaluated by the 
TUNEL assay. SHAM, sham group; MCT, monocrotaline group. Data are expressed as percentage of 
apoptotic cells and given as means ± SE. *p < 0.05 vs. control of the same group; #p < 0.05 vs. SHAM of 
the same TMP concentration; 
a
p < 0.05 vs. 20 μM of the same group; bp < 0.05 vs. 10 μM of the same 
group; 
c
p < 0.05 vs. 1 μM of the same group; dp < 0.05 vs. 0.1 μM of the same group. 
 
Higher concentrations of terameprocol (20 and 50 μM) induced apoptosis of cells in 
both SHAM and MCT groups, in a dose-dependent manner. In contrast, the lower doses 
of terameprocol (0.1, 1 and 10 μM) had no effect on apoptosis from cells of both 
groups. In addition, at 20 μM of terameprocol, the percentage of apoptotic cells was 
significantly higher in the SHAM group, compared to the MCT. 
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6.4. Proliferation of pulmonary artery smooth muscle cells – chronic studies 
Assays were performed during six days to evaluate the chronic cell response to 
terameprocol in the concentrations of 0, 20 and 50 μM. Results regarding SHAM and 
MCT groups are plotted in figure 7.  
 
 
Figure 7 – Chronic effect of terameprocol in the proliferation of pulmonary artery smooth muscle cells 
from the sham (A) and monocrotaline (B) groups, evaluated by trypan blue exclusion method. Data are 
expressed as cells/mL and given as means ± SE. *p < 0.05 vs. control (TMP 0 μM) of the same day; #p < 
0.05 vs. 20 μM of the same day; ap < 0.05 vs. day 5 of the same TMP concentration; bp < 0.05 vs. day 4 
of the same TMP concentration; 
c
p < 0.05 vs. day 3 of the same TMP concentration; 
d
p < 0.05 vs. day 2 of 
the same TMP concentration; 
e
p < 0.05 vs. day 1 of the same TMP concentration. 
 
In sham group there was an increase in cell proliferation over time, for all the TMP 
concentrations tested (0, 20 and 50 μM). However, cells treated with TMP 50 μM 
proliferated significantly less than control cells (TMP 0 μM) and cells treated with TMP 
20 μM. In contrast, cells treated with TMP 20 μM proliferated more than control cells. 
Regarding MCT group, it was observed that cell proliferation increased over time, in all 
the concentrations studied, but in day 5 it was observed a decrease in the case of the 
control and TMP 50 μM treated cells. For cells treated with TMP 20 and 50 μM, it was 
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observed that they proliferated significantly less than control cells. Cells treated with 
TMP 50 μM proliferated more than cells treated with TMP 20 μM until day 4. 
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7. Discussion 
Despite the beneficial effects of current drugs in the relief of the symptoms and in 
the improvement of the survival [30, 149], a more emphasis has been given to therapies 
that focus in targeting vascular remodeling in PAH [181, 182]. In this context, Rho 
kinase inhibitors, dichloroacetate, simvastatin, tyrosine kinase inhibitors and survivin 
inhibitors are being explored as potential therapies to enhance apoptosis and decrease 
cellular proliferation [181]. Between these strategies, survivin is an attractive target, 
once it regulates both proliferation and apoptosis. The beneficial effect of targeting 
survivin pathway is well known in the area of cancer treatment [5, 183]. This is a 
disease that similarly to PAH is characterized by excessive cellular proliferation and 
impaired apoptosis. The fact that survivin expression is observed in the majority of 
tumors and rarely expressed in normal healthy adult tissues makes this molecule a target 
to cancer treatment [183]. In the last years the research for anti-survivin therapy in 
cancer increased and there are several drugs in clinical trials [5, 183, 195-198]. 
Strategies targeting survivin act by binding to survivin promoter, by inhibiting protein 
translation, or by interfering with survivin function and examples include: anti-sense 
oligonucleotides (LY2181308), ribozymes, small interfering RNAs, dominant-negative 
mutants (Cys84Ala and Thr34Ala), and small-molecule antagonists [183]. In the last 
group is included terameprocol, a compound that was found to inhibit Sp1-dependent 
gene coding for survivin and cdc2 [6, 194]. In addition, it was reported that TMP cause 
growth arrest in several cancer types, both in vivo and in vitro. Regarding the safety of 
this drug, previous data showed no relevant toxicity [199]. 
The beneficial effects of survivin pathway inhibition in cancer have encouraged 
researchers to explore this therapeutic approach in other diseases also marked by 
impaired proliferation and apoptosis, such as PAH. Regarding this issue, until now, 
there is only one study that evaluated the expression of survivin and the effects of its 
inhibition in PAH. McMurtry et al. [4] showed that this pathway is up-regulated in 
patients with PAH and in rats injected with MCT. In addition, they also reported that 
targeting survivin pathway, through gene therapy with a survivin mutant (Thr34Ala), 
inhibiting the phosphorylation necessary for survivin functions in proliferation and 
apoptosis, MCT-induced PAH was reversed. Thus, survivin inhibition can be 
considered a candidate therapeutic target for PAH. However, the use of a 
pharmacological approach instead of gene therapy targeting survivin was not yet 
explored. In this work we evaluated the effect of terameprocol in the proliferation and 
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apoptosis of PASMCs primary cultures in PAH. Regarding the results related with 
cellular proliferation, evaluated by the BrdU assay (Figure 5), it was verified that 
terameprocol inhibits PASMCs proliferation from SHAM and MCT animals in a dose-
dependent manner. The results related with apoptosis, evaluated by TUNEL assay 
(Figure 6), showed that TMP induces PASMCs apoptosis, in both SHAM and MCT 
animals in a dose-dependent manner. In the case of cell proliferation, TMP inhibitory 
effect was observed from the concentration of 10 μM and continued until the maximum 
concentration tested. In the case of apoptosis, TMP induced markedly apoptosis only in 
the concentrations of 20 and 50 μM. However, in both studies, for the concentration of 
20 μM, TMP showed to have an anti-proliferative and apoptotic effect more marked in 
cells from SHAM group, comparing with MCT group cells. Once the concentrations of 
20 and 50 μM were those that showed to have more positive effects, in the acute studies, 
we then performed chronic assays to evaluate cell proliferation over time, during six 
days, through the trypan blue exclusion method. The results obtained were in agreement 
with the acute effect verified in the previous studies, showing an anti-proliferative effect 
of terameprocol. However, differences were observed between cells from SHAM and 
MCT groups. MCT cells showed a decrease in proliferation when treated with TMP 20 
and 50 μM and this response was more marked in the case of TMP 20 μM treatment 
(Figure 7B). In contrast, with cells from SHAM group (Figure 7A), a decrease in 
proliferation was only observed in the case of cells treated with TMP 50 μM. Thus, 
once MCT cells responded to lower TMP concentrations than SHAM cells, this 
suggests that MCT cells can be more sensitive to TMP effects, which can be related to 
the survivin over-expression in these cells, fact that was previously observed by 
McMurtry and colleagues in tissue lung of PAH patients and rats injected with MCT, 
through immunohistochemistry analysis [4]. 
In the current study, we used the MCT animal model of PAH. This animal model 
has been used for years to study the pathogenesis of PAH, as well as the effects of drug 
intervention [121, 126, 127]. Monocrotaline is a pyrrolizidine alkaloid converted in the 
liver in a toxic metabolite (MCTP), which mainly affects the hepatic and 
cardiopulmonary systems [128, 129]. Several studies reported the effects of MCT 
administration by different routes, doses and animal species [126, 142, 200]. Although 
variations of these factors contribute to the severity of the lesions, the general spectrum 
of effects is maintained and includes right ventricular hypertrophy, vasoconstriction, 
ECs hypertrophy, SMCs hypertrophy and hyperplasia and inflammation [122, 128, 
 43 
 
132]. Although there are some differences described between this animal model and 
human PAH (such as the absence of plexiform lesions in the experimental model) it has 
identical hemodynamic and some morphological features [122, 136]. In accordance, the 
results from hemodynamic evaluation revealed that MCT induced an increase in right 
ventricular peak systolic pressure (Table 4). This was associated with increased RV 
mass and cardiomyocyte hypertrophy, corroborating previous studies [126, 141, 142, 
200]. The RV hypertrophy is the result of pressure overload secondary to the pulmonary 
artery wall changes that obstruct lumen arteries and lead to an increase in PAR and PAP 
[29]. This mechanism is firstly a compensatory response, reflecting RV adaptation to 
the sustained afterload elevation. However, depending on the duration of this afterload 
elevation, cardiac hypertrophy can progress from a compensatory state to a systolic or 
diastolic dysfunctional state, and can culminate in right heart failure [31]. Although LV 
weight was not determined in this study, previous studies reported that left ventricle 
hypertrophy does not occur with MCT administration, but alterations in the contractile 
phenotype are reported [142]. The increase in the index L/ BW (Table 4) in this study 
suggests cellular hypertrophy and/or hyperplasia in the lung due to MCT administration. 
In the present study, we observed pulmonary arterial wall alterations (Figure 4C and D), 
namely increased pulmonary arterial wall thickness in MCT group, results previously 
reported in other studies [200].  
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8. Conclusion 
Aiming to evaluate the effect of terameprocol, an antagonist of survivin, in the 
proliferation and apoptosis of pulmonary artery SMCs in PAH, we used the 
monocrotaline animal model and studied the cellular response to this drug in primary 
cultures of this cell type. According to the results obtained it was possible to conclude 
that: 
i) terameprocol inhibited the proliferation of PASMCs isolated from animals 
injected with MCT; 
ii) terameprocol induced apoptosis of PASMCs isolated from animals injected with 
MCT; 
iii)  PASMCs isolated from animals injected with MCT seems to be more sensitive 
than PASMCs isolated from SHAM animals to the anti-proliferative 
terameprocol effect, suggesting a survivin over-expression in PASMCs primary 
cultures isolated from animals with MCT-induced PAH. 
 
Taken together, data suggest that terameprocol might be seen as a new attractive 
therapeutic approach to PAH. In the future, it will be important to study the molecular 
pathways underlying these effects of TMP in PASMCs, and it will be interesting 
evaluate the effects of direct administration of TMP in rats with PAH induced by MCT.   
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